Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Obesity, Non-Alcoholic Steatohepatitis
EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity
This study is designed to investigate the impact of weight loss achieved with the IGB on NASH with early fibrosis in a select cohort of patients with obesity preselected to have a high pre-test probability of having NASH with…
- Trial name
- NCT02880189
- Testing
- Orbera Intragastric Balloon, Endoscopic Ultrasound Guided Core Liver Biopsy
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH)
- Trial name
- CGH-LiNASH (NCT02654665)
- Testing
- Lifestyle modification, Liraglutide
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Bariatric Surgery Candidate, Nonalcoholic Steatohepatitis
Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric Surgery
Obesity and obesity related health problems are globally recognized as one of the major threats to public health. Bariatric surgery is the most effective and durable therapy option for obesity and the improvement of obesity…
- Conditions
- Bariatric Surgery Candidate, Nonalcoholic Steatohepatitis, Obesity
- Trial name
- NALKOSTEP (NCT02792634)
- Testing
- Sleeve-Gastrectomy, Roux en Y gastric bypass
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- RWTH Aachen University
Chronic Kidney Diseases, MAFLD
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can…
- Trial name
- NCT07391267
- Testing
- Semaglutide Oral Tablet, Standard medical treatment
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-Alcoholic Fatty Liver Disease, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
A study for evaluating the improvement effect on Metabolic dysfunction-associated steatotic liver disease (MASLD) of probiotics Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with dysbiosis of the…
- Trial name
- NCT04555434
- Testing
- Probiotics
- Where
- South Korea
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Nash
Psoriasis and Non Alcoholic Steatohepatitis: Is There a Shared Inflammatory Network ?
The study is to assess frequency of NASH in Psoriatic patient and to measure the level of proinflammatory cytokines including TNFα, interleukin (IL)-6 and IL-17 and anti-inflammatory cytokines including IL10, IL35 by ELISA.
- Trial name
- PANASH (NCT05994677)
- Volunteers
- 59 people
- Sponsor
- Assiut University
Non-alcoholic Fatty Liver Disease
Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver
We are doing this research study to evaluate whether continuous positive airway pressure (CPAP), a treatment for sleep apnea, will also help treat fatty liver disease.
- Trial name
- NCT01849081
- Testing
- CPAP, LIfestyle
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Nonalcoholic Steatohepatitis (NASH)
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH
- Trial name
- NCT05842512
- Testing
- ADI-PEG20
- Where
- 10 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- Polaris Group
Non-Alcoholic Fatty Liver Disease
Pilot of Lifestyle Behavior Intervention for Non-Alcoholic Fatty Liver Disease
The purpose of this study is to pilot test a behavioral lifestyle intervention for Hispanic/Latino patients with non-alcoholic fatty liver disease (NAFLD)
- Trial name
- NCT05200585
- Testing
- Healthy Liver/Hígado Sano program, Usual standard of care
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The University of Texas Health Science Center, Houston
Non-Alcoholic Fatty Liver Disease
Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.
Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.
- Trial name
- NCT05106049
- Testing
- serum Adiponectin
- Volunteers
- 90 people
- Sponsor
- Assiut University
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
The study will evaluate the effect of coadministration of a range of doses of DGAT2i with 1 dose of ACCi, on hepatic steatosis and the ability of DGAT2i to mitigate ACCi-induced elevations in serum triglycerides.
- Trial name
- NCT04399538
- Testing
- PF-06865571, PF-05221304
- Where
- 20 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Pfizer
NAFLD, Web
Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children
The web-based continuity of care intervention model to provide comprehensive nursing interventions for obese children with NAFLD, always tracking their performance status, enabling them to grasp the knowledge of healthy weight…
- Conditions
- NAFLD, Web, Childhood Obesity
- Trial name
- NCT05527938
- Testing
- web-based intervention
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shaoxing Maternity and Child Health Care Hospital
NAFLD, Type 2 Diabetes
Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients
Non Alcoholic Fatty Liver Disease (NAFLD) is an emergent disease worldwide, and soon the leading cause of hepatic transplant in the USA.
- Trial name
- NCT04493814
- Where
- France
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Non Alcoholic Steatohepatitis
Coffee Consumption and NASH in the French Population.
The aim of our study is to evaluate the effect of coffee consumption on the risk of severe liver fibrosis in French patients with NASH.
- Trial name
- COCANASH (NCT03432377)
- Where
- 16 sites in France
- Volunteers
- 107 people
- Sponsor
- Versailles Hospital
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States.
- Trial name
- NCT04031729
- Testing
- Aspirin 81 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
NASH - Nonalcoholic Steatohepatitis, NAS
Hepatic Energy Fluxes in NASH and NAS Patients
Diseases along the nonalcoholic fatty liver disease spectrum, which are tightly coupled to the obesity epidemic, are soon to become the commonest indication for liver transplantation in the United States.
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss
- Trial name
- NCT03997422
- Testing
- Vertical Sleeve Gastrectomy (VSG)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Nonalcoholic Steatohepatitis, Liver Fibroses
Liver Fibrosis in Peri-menopausal Women
This is a prospective observational study in a single medical center. The aim is to evaluate the status of fibrosis and steatosis of liver parenchyma in peri-menopausal women using noninvasive methods of vibration-controlled…
- Conditions
- Nonalcoholic Steatohepatitis, Liver Fibroses, Menopause
- Trial name
- NCT03602573
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chang Gung Memorial Hospital
NAFLD, Cardiac Disease
Cardiac Dysfunction in Patients with Fatty Liver Disease
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease.
- Conditions
- NAFLD, Cardiac Disease, Fatty Liver, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- NCT06386094
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.